Shots: Cue Biopharma will conduct a P-I KEYNOTE-A78 study assessing the combination therapy as 1L treatment for HPV+ advanced head and neck cancer. KEYNOTE-A78 will be conducted in parallel with the ongoing P-I study assessing CUE-101 as monothx. post 1L treatment The ongoing P-I dose-escalation and expansion study assessing CUE-101 as a monothx. in post […]Read More
Shots: The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit vs the CRT + PBO arm after a 2-year follow-up period The BTD reaffirms that Debio 1143 has the potential to offer benefit over the […]Read More
Shots: AstraZeneca will evaluate the combination of Monalizumab with Cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the anticipated onset of the study in 2020 In Apr’2015, AstraZeneca and Innate collaborated to co-develop & co-commercialize Monalizumab for $1.275B out of which Innate has received $350M and […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
